Tachihara M, Kiriu T, Hata A, et al. - In non-small-cell lung cancer (NSCLC) patients with prior platinum-based chemotherapy, researchers evaluated the effectiveness and safety of nanoparticle albumin-bound paclitaxel (nab-PTX) + gemcitabine (GEM)in combination. Until disease progression or occurrence of unacceptable toxicity, the participants were administered nab-PTX (100 mg/m2) + GEM (1,000 mg/m2) on days 1 and 8 of each 3-week cycle. Progression-free survival was the primary endpoint. There were 28 evaluable patients with a median age of 68 years (range 47–79); 23 were male and 5 were female. The median progression-free survival was estimated to be 3.1 months and the overall response rate was 17.9%. Findings revealed limited efficacy of the combination of nab-PTX with GEM in advanced second or third-line NSCLC patients. Also, interstitial pneumonia occurred frequently, which was not acceptable.